title: KIF-2C expression is correlated with poor prognosis of operable esophageal squamous cell carcinoma male patients.
abstract: To determine the prognostic significance of Kinesin family member 2C (KIF-2C) expression in patients with operable esophageal squamous cell carcinoma (ESCC), we conducted an immunohistochemical analysis of KIF-2C expression in 415 surgically resected primary tumor tissues and 40 adjacent non-cancerous tissues from patients with operable ESCC. The median duration of postoperative follow-up was 76.0 months. Higher KIF-2C expression was associated with significantly increased risks of higher pathologic tumor (pT) status (P=0.038) and poorer tumor differentiation (P=0.022). For the entire cohort, KIF-2C expression was not an independent factor significantly associated with overall survival (OS) (P=0.097) or disease-free survival (DFS) (P=0.152). In female patients, KIF-2C expression had no effect on OS (P=0.880) and DFS (P=0.864). However, OS (hazard ratio (HR)=1.480, P=0.013) and DFS (HR=1.418, P=0.024) were worse for male patients with high KIF-2C expression compared with male patients with low KIF-2C expression. Moreover, the OS and DFS of male patients with high KIF-2C expression were also significantly shorter compared with female patients with low KIF-2C expression (P=0.022, P=0.029) and female patients with high KIF-2C expression (P=0.014, P=0.018). Based on these findings, KIF-2C expression in tumor tissues promises to serve as an independent prognostic marker for male, but not female, patients with operable ESCC. Prognosis was worse for male patients with high KIF-2C expression compared with patients with the same pathologic tumor-node-metastasis (pTNM) stage.
authors: Department of Thoracic Oncology, Sun Yat-Sen University Cancer Center, Guangzhou 510060, Guangdong Province, China.
authors: Hao
authors: H
authors: Duan
authors: Department of Thoracic Oncology, Sun Yat-Sen University Cancer Center, Guangzhou 510060, Guangdong Province, China.|Guangdong Esophageal Cancer Research Institute, Guangzhou 510060, Guangdong Province, China.
authors: Xu
authors: X
authors: Zhang
authors: Department of Thoracic Oncology, Cancer Center of Guangzhou Medical University, Guangzhou 510095, Guangdong Province, China.
authors: Fei-Xiang
authors: FX
authors: Wang
authors: Department of Pathology, Sun Yat-Sen University Cancer Center, Guangzhou 510060, Guangdong Province, China.
authors: Mu-Yan
authors: MY
authors: Cai
authors: Department of Thoracic Oncology, Sun Yat-Sen University Cancer Center, Guangzhou 510060, Guangdong Province, China.
authors: Guo-Wei
authors: GW
authors: Ma
authors: Department of Thoracic Oncology, Sun Yat-Sen University Cancer Center, Guangzhou 510060, Guangdong Province, China.|Guangdong Esophageal Cancer Research Institute, Guangzhou 510060, Guangdong Province, China.
authors: Hong
authors: H
authors: Yang
authors: Department of Thoracic Oncology, Sun Yat-Sen University Cancer Center, Guangzhou 510060, Guangdong Province, China.|Guangdong Esophageal Cancer Research Institute, Guangzhou 510060, Guangdong Province, China.
authors: Jian-Hua
authors: JH
authors: Fu
authors: Department of Thoracic Oncology, Sun Yat-Sen University Cancer Center, Guangzhou 510060, Guangdong Province, China.
authors: Zi-Hui
authors: ZH
authors: Tan
authors: Department of Thoracic Oncology, Sun Yat-Sen University Cancer Center, Guangzhou 510060, Guangdong Province, China.
authors: Xia-Yu
authors: XY
authors: Fu
authors: Department of Thoracic Oncology, Sun Yat-Sen University Cancer Center, Guangzhou 510060, Guangdong Province, China.
authors: Qi-Long
authors: QL
authors: Ma
authors: Department of Thoracic Oncology, Sun Yat-Sen University Cancer Center, Guangzhou 510060, Guangdong Province, China.
authors: Xin-Ye
authors: XY
authors: Wang
authors: Department of Thoracic Oncology, Sun Yat-Sen University Cancer Center, Guangzhou 510060, Guangdong Province, China.|Guangdong Esophageal Cancer Research Institute, Guangzhou 510060, Guangdong Province, China.
authors: Peng
authors: P
authors: Lin
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis*; D002294:Carcinoma, Squamous Cell / Q000737:chemistry* / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D002454:Cell Differentiation; D018572:Disease-Free Survival; D004938:Esophageal Neoplasms / Q000737:chemistry* / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D000077277:Esophageal Squamous Cell Carcinoma; D016629:Esophagectomy / Q000009:adverse effects / Q000401:mortality; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D016547:Kinesins / Q000032:analysis*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D012307:Risk Factors; D012737:Sex Factors; D013997:Time Factors; D016896:Treatment Outcome; D015854:Up-Regulation
chemical_list: D014408:Biomarkers, Tumor; C091489:KIF2C protein, human; D016547:Kinesins
keywords: KIF-2C; esophageal squamous cell carcinoma; prognosis